statistiche ricercatore

Continente	#
EU - Europa	799
AS - Asia	410
NA - Nord America	254
SA - Sud America	76
Continente sconosciuto - Info sul continente non disponibili	16
AF - Africa	8
OC - Oceania	2
Totale	1.565

Nazione	#
RU - Federazione Russa	651
US - Stati Uniti d'America	238
SG - Singapore	138
CN - Cina	98
IT - Italia	75
BR - Brasile	58
VN - Vietnam	50
HK - Hong Kong	47
IN - India	24
DE - Germania	20
KR - Corea	19
IE - Irlanda	14
JP - Giappone	13
AR - Argentina	6
FR - Francia	6
GB - Regno Unito	6
MX - Messico	6
CA - Canada	5
AT - Austria	4
FI - Finlandia	4
NL - Olanda	4
PK - Pakistan	4
PL - Polonia	4
ZA - Sudafrica	4
BD - Bangladesh	3
CL - Cile	3
EC - Ecuador	3
ID - Indonesia	3
IR - Iran	3
MY - Malesia	3
SE - Svezia	3
AU - Australia	2
CO - Colombia	2
IQ - Iraq	2
NI - Nicaragua	2
PY - Paraguay	2
BG - Bulgaria	1
BO - Bolivia	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EG - Egitto	1
ES - Italia	1
IL - Israele	1
JM - Giamaica	1
KE - Kenya	1
MA - Marocco	1
PH - Filippine	1
PT - Portogallo	1
RO - Romania	1
RS - Serbia	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
TR - Turchia	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.549

Nome	#
Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence	155
Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab	147
Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis	140
Use of Transglutaminase 2 mRNA expression in peripheral blood mononuclear cells in patients with Radiologically Isolated Syndrome as a neuroinflammation biomarker: A preliminary study.	140
Vocabulary knowledge as a reliable proxy of cognitive reserve in multiple sclerosis: a validation study	137
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients	133
Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: The importance of intrathecal MOG-IgG synthesis	123
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey	122
The relationship between biological sex, cognitive reserve, and cognition in multiple sclerosis	121
Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease	120
Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders	117
MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment	110
Totale	1.565

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	10	0	0	0	2	4	0	0	0	0	1	0	3
2022/2023	20	2	0	1	0	1	1	0	1	10	0	2	2
2023/2024	27	0	0	4	0	3	2	0	1	5	1	7	4
2024/2025	175	3	1	4	1	23	21	14	16	18	24	23	27
2025/2026	1.223	67	103	69	49	101	593	89	43	30	23	31	25
2026/2027	109	9	19	70	11	0	0	0	0	0	0	0	0
Totale													1.565